Search research articles
Contact Us
Filters
Showing results (471-480 of 740) with videos related to
Page
of 74
Sort By:
Blood Cancer Journal
|
November 9, 2018
Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study
Despina Fotiou, Theodoros N Sergentanis, Loula Papageorgiou, et al.
Haematologica
|
February 22, 2024
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma
Maria Victoria Mateos, Katja Weisel, Evangelos Terpos, et al.
American Journal of Hematology
|
June 22, 2022
Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications
Efstathios Kastritis, Magdalini Migkou, Dimitra Dalampira, et al.
Anti-Cancer Drugs
|
May 29, 2004
Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG)
Jim Janinis, George P Stathopoulos, Pavlos Nikolaidis, et al.
Hemasphere
|
November 8, 2023
Management and Outcomes of Anti-CD38 Refractory Patients: The Impact of Retreatment and of Subsequent Therapies
Efstathios Kastritis, Foteini Theodorakakou, Ioannis Ntanasis-Stathopoulos, et al.
Haematologica
|
August 24, 2019
Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network
Philippe Moreau, Pieter Sonneveld, Mario Boccadoro, et al.
American Journal of Hematology
|
April 4, 2020
Cell-free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations
Ioannis Ntanasis-Stathopoulos, Tina Bagratuni, Maria Gavriatopoulou, et al.
Blood Cancer Journal
|
February 28, 2019
The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG)
Charalampia Kyriakou, Sean Molloy, Frank Vrionis, et al.
American Journal of Hematology
|
October 15, 2013
Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group
Eirini Katodritou, Evangelos Terpos, Charikleia Kelaidi, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 6, 2023
Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study
Sara Bringhen, Luděk Pour, Reuben Benjamin, et al.
Page
of 74
Search research articles
Search
Showing results (471-480 of 740) with videos related to
Sort By:
Page
of 74
Blood Cancer Journal
|
November 9, 2018
Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study
Despina Fotiou, Theodoros N Sergentanis, Loula Papageorgiou, et al.
Haematologica
|
February 22, 2024
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma
Maria Victoria Mateos, Katja Weisel, Evangelos Terpos, et al.
American Journal of Hematology
|
June 22, 2022
Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications
Efstathios Kastritis, Magdalini Migkou, Dimitra Dalampira, et al.
Anti-Cancer Drugs
|
May 29, 2004
Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG)
Jim Janinis, George P Stathopoulos, Pavlos Nikolaidis, et al.
Hemasphere
|
November 8, 2023
Management and Outcomes of Anti-CD38 Refractory Patients: The Impact of Retreatment and of Subsequent Therapies
Efstathios Kastritis, Foteini Theodorakakou, Ioannis Ntanasis-Stathopoulos, et al.
Haematologica
|
August 24, 2019
Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network
Philippe Moreau, Pieter Sonneveld, Mario Boccadoro, et al.
American Journal of Hematology
|
April 4, 2020
Cell-free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations
Ioannis Ntanasis-Stathopoulos, Tina Bagratuni, Maria Gavriatopoulou, et al.
Blood Cancer Journal
|
February 28, 2019
The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG)
Charalampia Kyriakou, Sean Molloy, Frank Vrionis, et al.
American Journal of Hematology
|
October 15, 2013
Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group
Eirini Katodritou, Evangelos Terpos, Charikleia Kelaidi, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 6, 2023
Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study
Sara Bringhen, Luděk Pour, Reuben Benjamin, et al.
Page
of 74